NCT01430351: Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy |
|
|
| Active, not recruiting | 1 | 144 | US | Mefloquine, Memantine Hydrochloride, Ebixia, Namenda, Metformin Hydrochloride, APO-Metformin, Cidophage, Dimefor, Glifage, Glucoformin, Glucophage, Glucophage ER, Metformin HCl, Riomet, Siofor, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma | 09/25 | 09/25 | | |